FDA Approves Pradaxa for Children - The Fritsma Factor

Jun 23 2021

George Fritsma

Thanks to Dean Willett, Precision BioLogic Inc., for today’s heads-up for this FDA announcement [click] approving dabigatran etixalate [Pradaxa®] therapy for children 3 months–12 years who have experienced venous thromboembolic disease.

Comments (0)

Anticoagulant Therapy

No comments here.

Leave a Reply Cancel reply

You must be logged in to post a comment.

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question